Use App
Trending
News
Earnings
All
DIA
0.12%
SPY
0.84%
QQQ
2.47%
Trending
DOGE
1.21%
SOL
4.38%
MULN
36.84%
SHIB
0.26%
ZEC
2.80%
AERO
9.84%
BTI
0.33%
AIOZ
14.13%
XRP
2.33%
DOGINME
0.37%
DOGE
1.21%
SOL
4.38%
MULN
36.84%
SHIB
0.26%
ZEC
2.80%
AERO
9.84%
BTI
0.33%
AIOZ
14.13%
XRP
2.33%
DOGINME
0.37%
home
Symbol
AMRN
news
AMRN
Amarin Corp - ADR
30,473
Mkt Cap
$315.74M
Volume
43,173.00
52W High
$20.90
52W Low
$9.98
PE Ratio
-9.29
AMRN Fundamentals
Price
$15.05
Prev Close
$14.84
Open
$14.82
50D MA
$14.66
Beta
1.02
Avg. Volume
67,538.46
EPS (Annual)
-$1.87
P/B
0.70
Rev/Employee
$2.68M
$7.15
PE Ratio
-9.29
Loading...
Loading...
Feed
News
Sentiment
Earnings
Fundamentals
Info
News
all
press releases
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
Theravance Q1 earnings top estimates as collaboration revenues grow, while restructuring and cost cuts aim to drive $60-$70M annualized cash flow.
Zacks
·
22h ago
Share to Feed
More News
VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings
Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.
Zacks
·
22h ago
Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus
XENE's Q1 loss matches estimates, while phase III azetukalner data, cash growth and late-stage pipeline progress stay in focus.
Zacks
·
23h ago
Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus
KOD posts a wider Q1 loss as research & development spending rises, while positive phase III Zenkuda data accelerate the regulatory plans.
Zacks
·
23h ago
BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates
Beam Therapeutics Q1 revenues beat estimates as its gene-editing pipeline advanced, with key updates across the SCD, AATD and PKU programs.
Zacks
·
23h ago
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.
Zacks
·
23h ago
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.
Zacks
·
1d ago
Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
INSM stock plunges 23% after Q1 sales miss estimates despite 230% revenue growth and strong Brinsupri uptake.
Zacks
·
1d ago
Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater China
VTRS beats Q1 estimates as revenues climb 8% on strong Greater China and brands sales, while management reaffirms 2026 guidance.
Zacks
·
2d ago
ADMA Q1 EPS Jumps 73% Y/Y, Revenues Slip, 2026 View Down
ADMA cuts its 2026 outlook after Q1 revenues slip amid IG market pressure, though Asceniv demand and margins stay strong.
Zacks
·
2d ago
<
1
2
...
>
Latest AMRN News
View
Advertisement
|
Remove ads.
Top Discussions
top
active
trending
Advertisement
|
Remove ads.
Advertisement
|
Remove ads.
Watchlist
Trending
News
Explore
Community
Profile